Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Amgen posts results for completed Phase 4 romosozumab and Phase 1 rocatinlimab trialsOct 23Weekly roundup, 4 itemsAmgenrocatinlimabUpdated
Inhibikase names Kailera CMO Scott Wasserman to board, Berman resignsOct 20PeopleIKT-001Inhibikase Therapeutics
Amgen registers new Phase 3 maridebart cafraglutide vs. semaglutide trial in type 2 diabetesOct 8Weekly roundup, 3 itemsAMG-513AmgenUpdated
Amgen updates IMDELLTRA label via BLA supplement; registers romosozumab bioavailability trialSep 11Weekly roundup, 2 itemsAmgenromosozumab-aqqg